Top

BMC Neurology

Published in:

Open Access 01-12-2021 | Giant Cell Arteritis | Case report

Tocilizumab-associated posterior reversible encephalopathy syndrome in giant-cell arteritis – case report

Authors: Michaela Butryn, Sabine Mewes, Eugen Feist, Oliver Beuing, Christian Müller, Jens Neumann

Published in: BMC Neurology | Issue 1/2021

Abstract

Backround

We describe one of the first cases of a Posterior reversible encephalopathy syndrome (PRES) under tocilizumab as treatment of Giant cell arteritis (GCA).

Case presentation

A 65-year-old female with known GCA and treatment with Tocilizumab (TCZ) developed a convulsive epileptic seizure for the first time. MRI was suggestive of PRES and an associated left sided occipital hemorrhage. Extensive high blood pressure values were not detected. The patient recovered within a week and no further seizures occurred under anticonvulsive medication.

Conclusion

PRES during the treatment with Tocilizumab hasn’t been described in GCA so far. There are single reports of an association between TCZ and PRES in other entities. Thus, a link between interleukin-6 and the integrity of the vasculature could be considered. The clinical consequence should be a stringent blood pressure monitoring in the ambulant setting of patients receiving TCZ.

Patil P, Karia N, Jain S, Dasgupta B. Giant cell arteritis: a review. Eye Brain. 2013;5:23–33. https://doi.org/10.2147/EB.S21825.CrossRefPubMedPubMedCentral

Scott LJ. Tocilizumab: a review in rheumatoid arthritis. Drugs. 2017;77(17):1865–79. https://doi.org/10.1007/s40265-017-0829-7.CrossRefPubMedPubMedCentral

Stone JH, Klearman M, Collinson N. Trial of Tocilizumab in Giant-cell arteritis. N Engl J Med. 2017;377(15):1494–5. https://doi.org/10.1056/NEJMc1711031.CrossRefPubMed

Gale S, Trinh H, Tuckwell K, et al. Adverse events in Giant cell arteritis and rheumatoid arthritis patient populations: analyses of Tocilizumab clinical trials and claims data. Rheumatol Ther. 2019;6(1):77–88. https://doi.org/10.1007/s40744-019-0139-5.CrossRefPubMedPubMedCentral

Hobson EV, Craven I, Blank SC. Posterior reversible encephalopathy syndrome: a truly treatable neurologic illness. Perit Dial Int J Int Soc Perit Dial. 2012;32(6):590–4. https://doi.org/10.3747/pdi.2012.00152.CrossRef

Apuri S, Carlin K, Bass E, Nguyen PT, Greene JN. Tacrolimus associated posterior reversible encephalopathy syndrome - a case series and review. Mediterr J Hematol Infect Dis. 2014;6(1):e2014014. https://doi.org/10.4084/MJHID.2014.014.CrossRefPubMedPubMedCentral

Kobayashi K, Okamato Y, Inoue H, Usui T, Ihara M, KAwamata J, et al. Leukoencephalopathy with cognitive impairment following tocilizumab for the treatment of rheumatoid arthritis (RA). Intern Med. 2009;48(15):1307–9. https://doi.org/10.2169/internalmedicine.48.1926.CrossRefPubMed

Rosa Júnior M, Borges ÉI, Fonseca APA, Fiorot JL, Balarini L, Valim V. Posterior reversible encephalopathy syndrome during treatment with tocilizumab in juvenile idiopathic arthritis. Arq Neuropsiquiatr. 2018;76(10):720–1. https://doi.org/10.1590/0004-282X20180093.CrossRefPubMed

Garfall AL, Lancaster E, Stadtmauer EA, et al. Posterior reversible encephalopathy syndrome (PRES) after infusion of anti-Bcma CAR T cells (CART-BCMA) for multiple myeloma: successful treatment with cyclophosphamide. Blood. 2016;128(22):5702. https://doi.org/10.1182/blood.V128.22.5702.5702.CrossRef

10.

Hefzy HM, Bartynski WS, Boardman JF, Lacomis D. Hemorrhage in posterior reversible encephalopathy syndrome: imaging and clinical features. Am J Neuroradiol. 2009;30(7):1371–9. https://doi.org/10.3174/ajnr.A1588.CrossRefPubMedPubMedCentral

11.

Fischer M, Schmutzhard E. Posterior reversible encephalopathy syndrome. J Neurol. 2017;264(8):1608–16. https://doi.org/10.1007/s00415-016-8377-8.CrossRefPubMedPubMedCentral

12.

Blecharz-Lang KG, Wagner J, Fries A, et al. Interleukin 6-mediated endothelial barrier disturbances can be attenuated by blockade of the IL6 receptor expressed in brain microvascular endothelial cells. Transl Stroke Res. 2018;9(6):631–42. https://doi.org/10.1007/s12975-018-0614-2.CrossRefPubMed

13.

Zhou CC, Irani RA, Dai Y, et al. Autoantibody-mediated IL-6-dependent endothelin-1 elevation underlies pathogenesis in a mouse model of preeclampsia. J Immunol (Baltimore, Md. 1950). 2011;186(10):6024–34. https://doi.org/10.4049/jimmunol.1004026.CrossRef

14.

Edvinsson L, Owman C, Sjöberg NO. Autonomic nerves, mast cells, and amine receptors in human brain vessels. A histochemical and pharmacological study. Brain Res. 1976;115(3):377–93. https://doi.org/10.1016/0006-8993(76)90356-5.CrossRefPubMed

Title: Tocilizumab-associated posterior reversible encephalopathy syndrome in giant-cell arteritis – case report
Authors: Michaela Butryn
Sabine Mewes
Eugen Feist
Oliver Beuing
Christian Müller
Jens Neumann
Publication date: 01-12-2021
Publisher: BioMed Central
Keywords: Giant Cell Arteritis
Giant Cell Arteritis
Magnetic Resonance Imaging
Magnetic Resonance Imaging
Tocilizumab
Arteritis
Epileptic Seizure
Posterior Reversible Encephalopathy Syndrome
Published in: BMC Neurology / Issue 1/2021
Electronic ISSN: 1471-2377
DOI: https://doi.org/10.1186/s12883-021-02231-7

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Tocilizumab-associated posterior reversible encephalopathy syndrome in giant-cell arteritis – case report

Abstract

Backround

Case presentation

Conclusion

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Backround

Case presentation

Conclusion

Please log in to get access to this content

Other articles of this Issue 1/2021

I can’t count, but I can beat you playing cards: a case report on autoimmune encephalitis

Retraction Note: In-hospital cerebrovascular complications following orthotopic liver transplantation: A retrospective study

SPOAN syndrome: a novel mutation and new ocular findings; a case report

Hemostasis functions are associated with hemorrhagic transformation in non-atrial fibrillation patients: a case-control study

Molecular epidemiology of hereditary ataxia in Finland

Current clinical practice in disabling and chronic migraine in the primary care setting: results from the European My-LIFE anamnesis survey